MVP和MOP方案治疗晚期非小细胞肺癌的临床疗效观察  

A Comparison of the Therapeutic of MVP and MOP Regimen for Treatment of Advanced non-small Cell Lung Cancer

作　　者：赵夕武[1] 李坚[1] 张兰石[1] 

机构地区：[1]镇江医学院附属医院呼吸内科,江苏镇江212001

出　　处：《镇江医学院学报》2001年第1期2-4,共3页Journal of Zhenjiang Medical College

摘　　要：目的 :比较长春地辛 (VDS)、丝裂霉素 (MMC)和顺铂 (DDP)组成的MVP方案及长春新硷 (VCR)、丝裂霉素和顺铂组成的MOP方案治疗晚期非小细胞肺癌的疗效。方法 :72例晚期非小细胞肺癌 (NSCLC)随机分成两组 ,每例至少化疗两疗程。疗效及毒性反应按WHO标准进行评价。结果 :MVP组有效率为 60 .5 % ,MOP组有效率为 2 3 .5 % ,两组比较有显著差异 (P <0 .0 5 )。对VCR耐药病例应用VDS后仍有良好疗效。MVP组的骨髓抑制和胃肠道反应较MOP组明显 (P <0 .0 5 )。结论 :MVP方案是治疗晚期非小细胞肺癌有效率较高的方案之一 ,其毒副反应可为多数病人所耐受。Objective:To evaluate the curative effects of MVP(MMC+VDS+DDP)regimen on advanced non-small cell lung cancer.Methods:72 cases of advanced nonsmall lung cancer were randomly divided into two groups.Each patient was received at least 2 cycles combinant chemotherapy.The efficacy and the toxicity were assessed according to WHO criteria.Result:The result showed that response rates of MVP regimen and MOP regimen were 60.5% and 23.5% respectively.There was statistical significant difference between them(P<0.05).And VDS also have good effect on patients who were resistant to VCR.Myclosuppression and gastrointestinal tract reaction in MVP group were serious than that in MOP group.Conclusion:MVP is one of high effective regimes used for treatment of advanced NSCLC,whose toxicity can be endured by large part of patients.

关 键 词：长春地辛 长春新验 非小细胞肺癌 联合化疗 治疗 

分 类 号：R734.205[医药卫生—肿瘤]